Biommune Appoints Thomas Gadek, PhD, To Board of Directors

Posted by:

pdficon_small Download this as a PDF

Vancouver, British Columbia, September 20, 2016 – bioMmune Technologies Inc. (“bioMmune” or the “Company”) (TSX.V: IMU), a biotechnology company that specializes in drug discovery and development, today announced the appointment of Dr. Thomas R. Gadek to its Board of Directors.

“Tom’s demonstrated success as a discovery scientist and his accomplishments in executive leadership make him a perfect fit for our board,” said Patrick Gray, CEO of bioMmune.  “We are very pleased to welcome Tom, as his expertise will greatly aid our ability to discover and develop life-saving therapeutics, thus creating significant value for our shareholders”.
Dr. Gadek has had an illustrious career in the biotechnology industry spanning 33 years.  He discovered and developed several novel first in class molecules addressing emerging protein therapeutic targets.  These efforts have been chronicled as an author on 54 peer reviewed publications and as an inventor on 64 issued and 76 pending United States patents.  Dr. Gadek initially gained experience and expertise at larger companies, 5 years at Syntex and 15 years at Genentech.  He founded the venture backed startup SARcode, where he was CEO.  Dr. Gadek engineered the target identification, lead discovery, and clinical proof of concept for the development of Lifitegrast, a treatment for dry eye.  This resulted in the acquisition of SARcode by Shire, and the approval of Lifitegrast by the FDA in 2016.  Throughout his career, Dr. Gadek has gained experience in many critical aspects of modern drug discovery and development.  His expertise covers the realm of immunology and inflammation, particularly in the fields of ophthalmology and dermatology.  As a renowned medicinal chemist, he has pioneered the understanding of the transfer of protein epitopes to small molecule scaffolds for the identification of inhibitors of protein-protein interactions.  Dr. Gadek obtained his Ph.D. in Chemistry from the University of California, Berkeley following a Bachelors degree from the University of Colorado and a Masters degree from MIT.

ABOUT BIOMMUNE TECHNOLOGIES INC.

BioMmune focuses on cancer, infectious and autoimmune diseases.  Three significant technologies are:

  1. Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells.
  2. Exploiting the regulation of calcium channel activity which is important for controlling cells involved in the immune system. By regulating these calcium channels, immune activity can be controlled in ways to improve their ability to combat cancers, infections and autoimmune diseases.
  3. Modulating CD74, a protein involved in the immune system and its ability to reject foreign materials including pathogenic microbes. Finding molecules that regulate CD74 activity will aid the immune system to combat infections and cancers and to control autoimmune diseases.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may we may not be successful in either preclinical or clinical trials and not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Patrick Gray, President and CEO
For more information contact:
Dr. Patrick Gray
(1)206-650-6575

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES

0

BioMmune, a 2016 TSX Venture Top 50 Company, Awarded Patent for Calcium Channel Monoclonal Antibodies

Posted by:

pdficon_small Download this as a PDF

Vancouver, British Columbia, June 29, 2016 – bioMmune Technologies Inc. (“bioMmune” or the “Company”) (TSX.V:IMU) has been awarded its first patent for monoclonal antibodies that modulate voltage gated calcium channels in immune cells. The patent was awarded from China for a period of 20 years.  Voltage gated calcium channels are validated drug targets for blood pressure, pain, and heart arrhythmia.  However, all currently approved calcium channel drugs are small molecules, while bioMmune’s patent covers monoclonal antibodies specific for immune cell targets. Monoclonal antibodies offer excellent safety profiles and have several additional advantages over small molecules, including high specificity, long half life, and the ability to deliver chemical payloads to target cells.

bioMmune also holds a patent in Australia for a separate technology, novel compounds that restore immune recognition of cancer cells and aid in their destruction. bioMmune has a growing patent portfolio covering its innovative technologies and therapeutic programs.

bioMmune was among the 2016 TSX Venture 50, a ranking of the top fifty performers on the TSX Venture exchange. Of more than 2,500 listed companies, bioMmune was one of the top ten biotechnology companies. These rankings are based on market capitalization growth, share price appreciation, and trading volume. The company is pursuing therapies that activate and enhance patients’ immune systems for therapeutic purposes.

ABOUT BIOMMUNE TECHNOLOGIES INC.

bioMmune focuses on immunotherapies against cancer, infectious and autoimmune diseases. The Company’s three significant technologies are based on:

  1. Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells.
  1. Exploiting the regulation of calcium channel activity for cells of the immune system. By regulating these calcium channels, immune activity can be improved to combat cancers, infections and autoimmune diseases.
  1. Modulating CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding molecules that regulate CD74 activity will aid the immune system to combat infections and cancers and to control autoimmune diseases.

On Behalf of the Board of Directors

Dr. Patrick Gray, CEO

For more information contact:

Dr. Patrick Gray
(206) 650-6765

Forward Looking Statements

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties and other factors and may cause actual results to differ materially from current expectations. The
Company does not undertake to revise any forward-looking statement to reflect events or circumstances that occur after the date of this press release.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

0

bioMmune Technologies Inc. at TakeStock! Alberta

Posted by:

pdficon_small Download this as a PDF

bioMmune Technologies Inc. is pleased to be participating in TakeStock! Alberta through a keynote speech by Chief Executive Officer and President Patrick W. Gray.

An excerpt from the original press release follows below.

Diversified Small Caps Coming to Calgary’s TakeStock! Alberta

June 6th, 2016

Calgary, AB – With a dozen sponsors and a line up of about 20 diversified public companies from technology to mining, TakeStock!AB will be hosting the 6th TakeStock Investor Forum at the Ramada Downtown. This one-day event will be held on Wednesday, June 15th from 9AM – 6pm and welcomes small cap investors, brokers and other financial professionals.

A High-Coupon Debt Capital Panel discussion will kick-off the Investor Forum at 9am in the Okanagan East room. Participants include: panel chair Elias Foscolos of Industrial Alliance Securities, Davis Vaitkulis from Bond Capital, John Mackay of Mosaic Capital, and Randy Thompson of Old Kent Road. Simultaneously in the Okanagan West room a series of Mining Technical Presentations are scheduled: Amerigo Resources (TSX:ARG), Balmoral Resources (TSX:BAR), Constantine Metal Resources (TSXV:CEM), Copper North Mining (TSXV:COL), and West Red Lake Gold Mines (CSE: RLF) for those wanting to learn more about technical aspects of the projects.

From 11:30am – 1:30pm some 14 small cap companies from across Canada will have 8 min/each to inform audiences of their unique competitive advantage in the marketplace and later answer questions in the Exhibit Hall. Presentations again will run concurrently so audience members may choose which set of public companies they wish to see. The Canadian Securities Exchange is sponsoring the 3-6pm Reception which wraps up the day. Tickets for the event are only $30 and available at www.takestockAB.com.

 

0

bioMmune Appoints Dr. Patrick Gray As New Chief Executive Officer And President

Posted by:

pdficon_small Download this as a PDF

April 22nd, 2016

Vancouver, British Columbia,- bioMmune Technologies Inc. (TSX.V:IMU), (“bioMmune” or the “Company”) (TSX.V:IMU), a company focused on harnessing the body’s immune system to fight cancer and autoimmune diseases, announces that Dr. Patrick W. Gray has been appointed to serve as Chief Executive Officer and President. Dr. Gray has worked in the biotechnology industry for the past 35 years with extensive experience in drug discovery at Genentech, ICOS, and Macrogenics. He also has previous executive experience as Chief Scientific Officer, CEO, and as member of Boards of Director. His previous drug discovery efforts led to the development of the Hepatitis B vaccine and multiple drugs (such as Interferongamma) and drug targets (CCR5 and PI3 Kinase p110delta). Former bioMmune CEO and President, Dr. Reinhard Gabathuler has resigned his positions to become Senior Vice-President of Business Development. In his new role, Dr. Gray will lead the company’s R&D programs and financing activities, whereas Dr. Gabathuler will lead the company’s partnering and business development activities. BioMmune anticipates increasing partnering efforts resulting from its progress in its oncology and immunology programs.

ABOUT BIOMMUNE TECHNOLOGIES INC.

BioMmune focuses on cancer, infectious and autoimmune diseases. Three significant technologies are:

1. Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells.

2. Exploiting the regulation of calcium channel activity which is very important for controlling cells involved in the immune system. By regulating these calcium channels, immune activity can be controlled in ways to improve their ability to combat cancers, infections and autoimmune diseases.

3. Modulating CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding molecules that regulate CD74 activity will aid the immune system to combat infections and cancers and to control autoimmune diseases.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may we may not be successful in either preclinical or clinical trials and not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Karoly Nikolich, Director

For more information contact:
Dr. Patrick Gray
206-650-6575

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

0

BioMmune 2016 Report

Posted by:

As BioMmune Technologies remains engaged in the field of immunotherapy and the discovery and development of new therapeutics that enable the body’s own immune system to recognize and attack infections, cancers and autoimmune diseases, 2015 represented an important step forward for the company in its quest to fulfill this mandate.

The BioMmune Technologies 2016 Report looks back at the key moments of the past year.

On behalf of the entire BioMmune Technologies team, we thank our investors for their continued support in 2015 and into 2016.

0
Page 1 of 3 123